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Abstract
Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, is an immune-mediated, chronic relapsing disorder characterised by severe gastrointestinal symptoms that dramatically impair patients’ quality of life, affecting
psychological, physical, sexual, and social functions. As a consequence, patients suffering from this condition may perceive
social stigmatisation, which is the identification of negative attributes that distinguish a person as different and worthy of
separation from the group. Stigmatisation has been widely studied in different chronic conditions, especially in mental illnesses and HIV-infected patients. There is a growing interest also for patients with inflammatory bowel disease, in which
the possibility of disease flare and surgery-related issues seem to be the most important factors determining stigmatisation.
Conversely, resilience represents the quality that allows one to adopt a positive attitude and good adjustments despite adverse
life events. Likewise, resilience has been studied in different populations, age groups, and chronic conditions, especially
mental illnesses and cancer, but little is known about this issue in patients with inflammatory bowel disease, even if this
could be an interesting area of research. Resilience can be strengthened through dedicated interventions that could potentially
improve the ability to cope with the disease. In this paper, we focus on the current knowledge of stigmatisation and resilience
in patients with inflammatory bowel disease.
Keywords Crohn’s disease · Quality of life · Ulcerative colitis
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Introduction
Inflammatory bowel disease (IBD) comprises Crohn’s disease (CD), ulcerative colitis (UC) and IBD unclassified for
patients where the diagnostic distinction between CD and
UC remains uncertain [1, 2]. IBD is an immune-mediated
chronic condition for which currently no definitive cure is
available. The natural history of IBD is characterised by
periods of remission and relapse [3, 4]. While some patients
may experience long periods of remission, others may experience a rather aggressive course with rapid disease progression [5]. In UC, mucosal inflammation is limited to the
colon, typically extending proximally from the rectum [1]. In
contrast, CD may affect any part of the gastrointestinal tract,
from the mouth to the anus, and is characterised by skip
lesions, and carries the risk of developing fistulas, strictures,
and abscesses [2]. Our understanding of the pathophysiology
leading to the development of IBD remains incomplete [6].
Most likely, there is a complex interplay of reduced intestinal barrier function, an overshooting intestinal immune
response to pathogen presentation, genetic predisposition,
and environmental triggers [7].
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IBD is a relatively common disease with an estimated
incidence of UC at 24.3 per 100,000 and CD at 12.7 per
100,000 person years in Europe [8]. Similar incidence rates
are seen in other developed nations, but there has been a
recent rise in its incidence in developing nations [8]. IBD
can develop at any age, but peak incidence is in early adulthood, with a second peak in patients over 65 years of age. As
mortality from IBD is relatively low, the prevalence of IBD
is rising [9]. Medical treatment for IBD includes mesalazine therapy—for UC only—with immunosuppressive treatment for CD and UC cases not controlled by mesalazine.
Advanced medical therapy of IBD includes biological treatments with anti-tumour necrosis factor α agents, anti-integrin agents, and agents against interleukin-12/23. Recently
the small molecule tofacitinib has been approved for UC and
many other molecules are currently in development. While
the above agents are effective in inducing response and
remission in IBD, at least a third of patients do not respond
to medical therapy [1, 2]. There remains a high need for
surgical intervention in IBD.
The symptoms of IBD can vary depending on diagnosis and phenotype, but very often include diarrhoea, bleeding per rectum, anaemia, abdominal pain and weight loss
[1, 2]. In addition, patients with CD may experience fistula discharge, abscesses or bowel obstruction due to the
development of strictures [2, 10], whereas severe colonic
inflammation in UC may lead to toxic megacolon [11]. All
the aforementioned factors largely justify the high psychological burden for patients with IBD. Anxiety and depression affect many patients with IBD [12, 13] and this is often
associated with poor disease outcomes. Anxiety may be
driven by physical symptoms and the fear associated with
experiencing those. For example, worry about incontinence
in patients with diarrhoea may lead to anxiety and social
isolation. Importantly, medications such as corticosteroids,
which are widely prescribed for the management of flares,
may in themselves precipitate anxiety and depression [14].
The patients may also become fearful of potential disease
complications leading to hospital admission, need for resection surgery or the development of IBD-related colorectal
cancer [3]. These fears may often be in excess of the actual
risk of such a complication. The patients may fear surgical treatment for the risk of needing a stoma and medical
treatments over concerns of potentially severe complications
from immunosuppressive therapy. In addition, misinformation or unchecked information sources can be associated
with a higher risk of anxiety [15].
In summary, patients with IBD experience disabling
physical symptoms might need life-changing surgery and
a have higher level of psychological distress and illnesses.
These challenges will undoubtedly also affect their social
and work life. This article provides the most recent insights
regarding stigmatisation that IBD patients may experience
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and the resilience and coping skills involved in dealing with
their disease.

Literature search strategy
Figure 1 shows the flow diagram of paper selection. During the first week of September 2019, we searched Medline
(PubMed) using the medical subject heading terms “stigmatisation”, “stigma*”, and “resilience” alone or matched
with “inflammatory bowel disease”, “Crohn’s disease”,
and “ulcerative colitis” for all articles published in English
since inception, focusing on the research question of this
review, i.e., the evaluation of stigmatisation and resilience
in patients with IBD, with any of the available scales. Two
authors independently searched the electronic database for
papers dealing with stigmatisation (MVL, SC) and resilience
(JG, MVL) in IBD patients. More than 1000 papers were
found with this search strategy, the majority of which were
unrelated to the subject of this review and were not considered (see Fig. 1). We, therefore, selected only landmark studies and relevant review articles for the general description
of stigmatisation and resilience, focusing instead on original
papers dealing with this issue in adult IBD patients. Finally,
we also searched the reference lists of pivotal review articles
for additional papers we judged to be relevant to this review.

Stigmatisation: definition
and how to measure it
Stigmatisation can be defined as the identification of negative attributes that distinguish a person as different and worthy of separation from the group, often leading the person
losing social status and facing discrimination [16]. Social
stigma is a complex and continually evolving phenomenon.
It includes one’s own perception, the internalisation of negative behaviours held by other subjects, and the implementation of behaviours by other subjects [17]. Therefore, it is
usually divided into three main domains. “Enacted stigma”
is “stigma put into practice” and represents direct social
discrimination and discriminatory experiences. “Perceived”
or “felt stigma” relates to individuals feelings that other
subjects have negative attitudes or negative beliefs about
them and their condition. “Internalised stigma” or “selfstigmatisation” occurs when stigmatised individuals begin
to conform to social mentality and to believe that stereotypes
about their condition are actually true and apply to themselves [18]. A fourth recognised domain called “resistance
to stigma” has been identified by some researchers using
the stigma scale for mental illness (ISMI) and has been
described as an adaptive response [19].
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Papers identified
through electronic
database searching
(Pubmed)

Excluded papers

Included papers

«Stigmatisation» or «stigma*»
(n= 6190)

Duplicates, not relevant for
the objective of the review
(n= 6170)

How to define and measure
stigma, background
(n= 20)

«Stigmatisation» or «stigma*»
AND
«inflammatory bowel disease»
(n= 53)

Duplicates, review article, not
pertinent with research
question
(n= 24)

Papers assessing
stigmatisation in inflammatory
bowel disease patients
(n= 29)

«Resilience»
(n= 24082)

Preliminary abstracts, review,
not in English
(n= 24066)

How to define and measure
resilience, background
(n= 16 )

«Resilience»
AND
«inflammatory bowel disease»
(n= 71)

Duplicates, animals, not
pertinent to research
question
(n= 58)

Papers assessing resilience in
inflammatory bowel disease
patients
(n= 13)

Fig. 1  Flow diagram of paper selection that was performed through
Pubmed for articles written in English. The main research question
regarded the evaluation of stigmatisation and resilience in patients
suffering from inflammatory bowel disease. The medical subject

heading terms “Crohn’s disease” and “ulcerative colitis” were also
used. More general articles dealing with how to define and how to
measure stigmatisation and resilience were used to provide background for the purpose of the review

In each victim of stigmatisation, we can recognise any
of the four domains of stigma and the relationship between
each of them and the impact on patients’ health and wellbeing is well documented in the literature [20–22]. Indeed,
the entity of stigmatisation depends on many factors, involving the patient, the disease, and the social context.
The stigmatisation of subjects suffering from mental illnesses has a long historical tradition, as proven by the fact
that the word “stigmatisation” derives from "stigma" which
is the mark that in ancient Greece was applied to slaves and
criminals [23]. In the following millennia, society did not
treat people who suffered from depression, autism, schizophrenia, and any other mental illness much differently to
slaves and criminals. Subjects suffering from psychiatric
illnesses were imprisoned, tortured, and sometimes even
murdered [23]. Stigmatisation of mental illness has been
identified as a critical health problem. Individuals who suffer
the effects of stigmatisation due to their mental illness have
a reduced life expectancy, not only due to the increase in
suicides or self-harm, but due to a reduction in their physical
health [24]. Such reduction is not only the consequence of
both the side effects of medicines and lifestyle, but also of
limited accessibility to the health services and an impaired
general quality of life [24].
Besides mental illnesses, social stigmatisation is
also associated with other chronic conditions. The most

emblematic example is represented by patients suffering
from HIV infection, who are often stigmatised due to the
association of this disease with behavioural factors, such
as intravenous drug abuse, and sexual promiscuity [25]. A
meta-analysis based on 64 studies showed that higher levels of depression, reduced levels of social support, reduced
levels of adherence to anti-retroviral therapy, and reduced
access to the social services were found in HIV-infected
patients who perceived high stigma [26]. Similarly, patients
with lung cancer can be stigmatised due to the strong connection of the disease with cigarette smoking [27]. In lung
cancer patients, it was shown that the perception of stigma
resulted in increased severity of depression, anxiety and
overall severity of cancer-related symptoms [28]. Among
others, patients with epilepsy may perceive the stigma due
to the symptoms and the care burden they exert on their
loved ones, such as the inability to drive [29]. Patients with
a functional illness, such as fibromyalgia, chronic fatigue
syndrome, and irritable bowel disease (IBS), experience
stigmatisation in relation to the fact that other people neither
believe to the authenticity of their condition and, therefore,
do not validate nor believe their experiences and symptoms
exist [30].
Stigmatisation is assessed throughout the use of different scales, depending on the specific disorder. In patients
with psychiatric diseases, the ISMI scale is most commonly
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used [19], while the HIV stigma scale [31] and the IBS perceived stigma scale (PSS) [32] are used for HIV and IBS
patients, respectively. The same PSS used for IBS patients
was also applied to IBD patients [17]. The PSS–IBD is a
self-administered scale consisting of 20 statements, equally
divided between significant others (friends, family members,
spouse or partner) and health care providers (doctors, nurses,
therapists, or other people who provide medical care). Each
score is obtained by dividing the sum of the single item
scores by the total number of answered items. Higher scores
denote greater perceived stigma, with a range of 0 (never) to
4 (always) per every single statement.

Stigmatisation in inflammatory bowel
disease
IBD mainly affects young adults with symptoms ranging
from abdominal pain and diarrhoea, to fever, weight loss,
malnutrition, and intestinal obstruction requiring hospitalisation [33]. These conditions are clearly susceptible to stigmatisation, mainly because of their symptoms, the incorrect
historical assumption of being psychosomatic conditions,
and given that they may deeply affect sexual life and body
image [34]. Intestinal symptoms can be detrimental to the
patient, in particular in a social setting, as the taboo around
such symptoms is still widespread in many cultures [17].
Furthermore, while today IBD aetiology places it in the field
of immune-mediated diseases, in the past they were seen
as psychosomatic illnesses in which one’s personality traits
made him/her susceptible to its manifestations. The notion
that a person could develop CD because of his/her "obsessive behaviour" could explain stigmatisation [35].
The patients with IBD frequently report problems related
to stigmatisation, including being treated differently, having a stoma bag, and being a burden to others [36–38].
An American study recruiting patients online and through
the Crohn’s and Colitis Foundation showed that perceived
stigma is a significant predictor of poor outcomes in IBD
patients, playing a role in the quality of life of patients with
detrimental effects similar to those seen in other chronic diseases [39]. The activity of the disease did not correlate with
stigma perception. This may be due to the constant worry
over potential flares rather than just over current symptoms
[39].
Data regarding perceived stigma in IBD and IBS are
controversial. Looper et al. did not find any significant difference in a study from 2004 [40], while a later study on
a much larger cohort showed that IBS patients perceiving
moderate-to-high stigma were three times more common
than those with IBD [17].
There is now a substantial body of evidence regarding
the importance of stigmatisation in IBD. These studies have
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focused on the various domains of stigmatisation, including
perceived, internalised, and enacted stigma (Table 1) [17, 36,
38–64].
Perceived stigma in IBD was evaluated first in 1989, showing how the functional impairment experienced by patients
was greater in their social and psychological rather than in
their physical dimensions [36]. Moreover, CD patients were
affected by a higher degree of perceived stigma compared
to UC patients. A cross-sectional survey of 611 UK patients
with IBD revealed that concerns about how other people
perceived IBD led to social withdrawal and isolation, in an
effort to protect themselves from potential shame [55]. These
findings were confirmed by a subsequent study showing how
perceived stigma indirectly worsened depression and favoured
social isolation [63]. A cross-sectional survey involving 2002
IBD patients from 8 countries showed that disease-related concerns varied considerably, probably due to differences in social
and economic background [48]. The study highlighted the relevance of surgery, the possibility of having an ostomy, uncertainties and unpredictability of disease course, and treatment
side effects. Additionally, patients often reported concerns
about being a burden to others, of feeling dirty, and of having
sexual and intimacy difficulties due to their disease [48].
Studies evaluating the effect of internalised stigma in IBD
patients have shown how one-third of patients reported internalised stigma in addition to alienation and social withdrawal
and how most engaged in stigma resistance behaviours [57].
Furthermore, it has been demonstrated that self-blame correlates with poor outcomes and leads IBD patients to avoid
coping strategies [54]. Ostomy was shown to be associated
with self-stigma due to the feeling of shame related to it [52].
Finally, the enacted stigma was evaluated in several studies, generally showing how being affected by IBD has an
impact on working life, as IBD patients are more likely to
encounter difficulties in finding a job and getting a promotion [43–45]. Disappointingly, 30% of work managers would
not provide time off to their employee to attend outpatient
clinic appointments [44, 45]. More recently, the enacted
stigma was evaluated in a cohort of college students showing that better awareness of the disease reduced stigma [62].
As most of these studies were conducted in the late 1990s
and early 2000, and given that only a few more studies have
been published since the last systematic review dealing with
this issue [34], there is an urgent need to carry out further
studies assessing stigmatisation related to IBD.

Resilience: definition and how to measure it
Studies on resilience vary in their methodology and samples [64–66]. Historically, most studies focused on difficult
environmental circumstances and children’s ability to thrive
and withstand the risk factors in their surroundings [67, 68]
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Table 1  Relevant studies exploring stigmatisation in patients with inflammatory bowel disease
Authors

Year Country

Type of stigma

Sample size

Key points

Wyke et al.

1988 UK

Perceived, enacted

170

Drossman et al.

1989 USA

Perceived

150

Salter

1990 USA

Internalised

Not clear

Mayberry et al.

1992 UK

Enacted

58 (CD only)

Moody et al.

1992 UK

Enacted

53

Mayberry

1999 UK

Enacted

195 (personnel managers)

Moody et al.

1999 UK

Perceived

64

Moskovitz et al.

2000 Canada

Perceived

86

de Rooy et al.

2001 Canada

Perceived

241

Levenstein et al.

2001 Cross-national Perceived, internalised

Daniel

2002 USA

Perceived, enacted, internalised 5

Krause

2003 Chile

Internalised

19

Looper and Kirmayer 2004 Canada

Perceived

89 (51 IBD)

Finlay et al.

2006 USA

Perceived

148

Smith et al.

2007 USA

Internalised

195 (71 with IBD)

Simmons et al.

2007 UK

Internalised

51

Taft et al.

2009 USA

Perceived

211

Most individuals disclosed IBD,
most co-workers/employers
were understanding, IBD led to
changes in work
Most common concerns related to
surgery, energy level and body
image
Ostomy allows “to control” the
disease, feeling clumsy during
sexual intercourse
Unemployment, CD patients
more likely to conceal their
disease to employers
Employers unwilling to employ
an individual with IBD and to
give time off to attend clinics
Unwillingness to provide time to
see the physician, IBD jeopardises promotions
Many students complain of
teachers not being sympathetic,
underachievement due to ill
health
Poor social support is related to
worse surgical outcomes
Greater stigma perceived by
elderly, females, patients with
UC, and with low level of
education;
Complications and variable
disease evolution elicit concern;
specific issues vary among
countries
Impaired body image, feeling
different, ashamed and worried
about others thinking IBD is
used for secondary gain
IBD as illness that invades all
dimensions of life
Higher level of perceived stigma
in functional disorders vs other
medical conditions (including
IBD)
Major differences across ethnic
groups regarding knowledge of
disease and social support
Disgust related to low colostomy
adjustment, low life satisfaction, low quality of life and to
stronger feelings of stigmatisation
Stoma acceptance, interpersonal
relationship and location of
the stoma were associated with
adjustment
Perceived stigma affects quality
of life

2002
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Table 1  (continued)
Authors

Year Country

Type of stigma

Sample size

Voth and Sirois

2009 UK

Internalised

259

Taft et al.

2011 USA

Perceived

Dibley and Norton

2013 UK

Perceived

Czuber-Dochan et al. 2013 UK

Perceived

Taft et al.

Internalised

2013 USA

Czuber-Dochan et al. 2014 UK

Enacted

Frohlich

2014 USA

Perceived

Saunders

2014 UK

Perceived

Bernhofer et al.

2017 USA

Perceived

Rohde et al.

2018 USA

Enacted

Gamwell et al.

2018 USA

Perceived

Dibley et al.

2019 UK

Perceived, internalised

Key points

IBD self-blame is related to
poorer outcomes
496
Greater stigma in IBS than IBD,
patient outcomes more affected
in stigmatised IBD patients
611
Emotional and psychological
impact, feelings of stigma,
limited lives, practical coping
mechanisms
46
IBD-related fatigue not addressed
in medical consultations
191
Social isolation common due to
stigma
20 (healthcare professionals) IBD-related fatigue poorly
understood
14
Feeling stigmatised by partner,
healthcare professionals, and
colleagues
16
Non-disclosure because of shame
may lead to experiencing blame
16
Feeling labelled as unable to
tolerate pain
127
Enacted stigma among college
students decreases when IBD is
disclosed
80
Indirect effect of perceived stigma
on depressive symptoms as it
impacts on social belongingness
18
Kinship stigma is present in IBD
patients

CD Crohn’s disease, IBD inflammatory bowel disease, IBS irritable bowel syndrome

Resilience, from the Latin verb "resilire", means rebound
or recoil [69]. The most commonly used description for
medical purposes involves the ability to adapt well in the
face of adversity [70]. Recently, Ungar recommended to
standardisation of research on resilience by defining three
distinct parts: (1) risk exposure, (2) desired outcome, and
(3) protective factors [67]. However, resilience is a dynamic
process that grows over time [65].
Resilience among patients with a chronic illness is often
defined as an individual’s ability to cope well in the face
of disease [71]. Literature reviews on chronic illnesses and
resilience revealed a paucity of articles including adults
compared to children [72, 73]. However, resilience was
either defined as a set of personal traits or as an outcome. In
cancer patients undergoing treatment [74], higher levels of
resilience were positively related to higher levels of activity and lower levels of psychological distress. In a study of
the relation between self-silencing and resilience in women
with HIV, higher rates of silencing were associated with
lower levels of resilience [75]. Furthermore, higher levels
of income, education, and employment were significantly

13

associated with resilience. A review of 12 cross-sectional
studies on resilience and chronic illness showed that resilience was both a significant predictor and outcome of recovery and quality of life in individuals living with a chronic
condition [71]. Hence, resilience can be considered as a part
of a patient’s clinical complexity [76].
There is a multitude of scales measuring resilience mostly
unique to the sample or specific situation researched. A comprehensive review by Windle et al. concluded that of 15
original scales examined many lacked sufficient information
regarding the psychometric ratings and theoretical underpinning of the scales [77]. Three scales were regarded as having more robust psychometric properties, Connor–Davidson
resilience scale (CD-RISC) [78], resilience scale for adults
(RSA), and the brief resilience scale (BRS) [79, 80].
The BRS contains six items of resilience with higher
scores indicating higher levels of resilience [80]. The BRS
assesses individuals’ traits of resilience and their ability to
cope with stress. It was initially tested on samples of cardiac
rehabilitated and fibromyalgia patients. Similarly, the RSA
measured 5 domains of resilience with 37 items, namely

Internal and Emergency Medicine (2020) 15:211–223

personal competence, personal structure, social competence,
social support, and family coherence [79]. It was originally
tested on a sample of psychiatric outpatients. The scale was
later reduced to 33 items and used a semantic differential
scale format for higher accuracy [81]. Lastly, the CD-RISC
comprises 25 items, also measuring trait resilience on a fivepoint Likert scale [78]. Like the RSA, CD-RISC was first
assessed among a sample of psychiatric patients. To this
day, the CD-RISC has been translated into over 70 different languages and is by far the most widely used scale of
resilience [82].

Resilience in inflammatory bowel disease
Although IBD imposes a mental and physical toll on individuals [83], some individuals do report feeling stronger due
to having IBD [84].
Most studies included in this review (Table 2) investigated psychological resilience and trait resilience that promoted the ability to bounce back from IBD-related adversity [85–97]. Some demographic characteristics found to be
relevant to individuals with IBD included being optimistic,
older [85], male, employed, not religious, and nulliparous
[86]. Women with IBD more commonly reported resilience
to be an essential determinant of health and both genders
mentioned self-efficacy, social support, occupational balance, and job satisfaction as the main determinants of health
[87]. Women with IBD and high resilience showed changes
in brain-behavioural patterns, whereas the results were not
conclusive for male participants [88]. Individuals whose
onset of CD occurred later in life (after 30 years of age)
and who performed complimentary activities appeared to
be more resilient [86]. These findings were corroborated by
Taylor et al.’s study, which compared level of physical activity, resilience, and health-related quality of life (HRQOL)
among IBD participants [89]. A higher intensity of physical activity independently and significantly predicted a
higher level of physical HRQOL, but not mental HRQOL.
Resilience, on the other hand, was a significant and positive
impact on mental HRQOL.
Sehgal et al. found that lower levels of resilience were
associated with significantly higher levels of anxiety and
clinical depression [90]. Conversely, higher levels of resilience were found to predict better quality of life among IBD
patients.
Higher levels of resilience predicted higher levels of
adaptation to the ostomy; notably, perseverance—defined
as a trait of resilience was the most reliable predictor [91].
Moreover, lower income, sleep disturbances and being
unmarried negatively impacted the level of resilience and
depression among CD patients with an ostomy. Resilience
was not significantly affected by clinical characteristics in
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UC patients. Overall, there was a slightly higher resilience
level among UC patients compared to CD patients [92].
Contrarily to the previous studies, Sirois and Hirsch
drew a distinction and defined resilience as a set of traits
that only promote the ability to recover from an illness [93].
The authors contrasted the concept of resilience with one’s
ability to thrive, the latter entailed growth above and beyond
the recovery. The study examined illness acceptance, coping
efficacy, depressive symptoms, and perceived social support
differences among IBD patients who experienced loss, resilience, and thriving. At baseline, results indicated that across
the four outcomes coping efficacy significantly distinguished
those who thrived versus those who were resilient. 6 months
later, this difference was no longer statistically significant.
However, both resilient and thriving IBD groups were consistently reporting better psychological outcomes compared
to the individuals experiencing loss from their illness.
Stress resilience was investigated in two studies [94, 95].
Melinder et al. examined prospectively a large cohort of
young men from the general Swedish population speculating that low-stress resilience would predict the onset of IBD.
Three quarters of subsequently diagnosed individuals had
low to moderate levels of stress resilience. Skrautvol and
Naden examined qualitatively stress resilience through integrative care [95]. The highly select interviewees dealt with
IBD using complementary and alternative medicine (CAM)
and dietary supplements stressing the perceived importance
of individualising treatment plans and making changes in
their lifestyle. These findings go in line with Sirois’ findings
that 46% of individuals with IBD used CAM as a complementary treatment to conventional medicine [96]. Although
the magnitude of the relation was small, individuals with
IBD who reported high perception of health and high levels
of resilience had greater odds of using CAM.
During transition from juvenile to adult-centred care,
both self-efficacy (SE) and resiliency were found to independently and significantly predict better transition [97].
In response, Carlsen et al. developed an e-health transfer
concept to assess patient-reported outcomes, including selfefficacy, resilience, stress response among adolescents with
IBD transitioning to healthcare [98].
Resiliency and IBD only began to be investigated during
the last 5 years. In most studies, resiliency was perceived as
a series of traits or psychological resilience, only one study
defined resiliency as a dynamic process [85], and two others
looked at stress resilience [94, 95]. There also seemed to be
some disagreement on whether the definition entails to thrive
or restore former health [93]. Moreover, the dominance of
cross-sectional data, small size, and purposive samples, as
well as the near absence of longitudinal studies, are some
of the shared limitations across the reviewed articles [99].
Stigmatisation and resilience share many common features (Fig. 2), some of which are IBD specific, and it is
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Table 2  Relevant studies exploring resilience in patients with inflammatory bowel disease
Authors

Year Country Measured resilience

Sample size

Sirois

2014 Canada

155 (IBD)

Trait resilience

Key points

High perception of health and high
levels of resilience had greater
odds of using CAM
Dur et al.
2014 Austria Psychological resilience
15 adults (CD)
Resilience appeared to be more salient and relevant to women vs men
Kilpatrick et al.a
2015 USA
Psychological resilience
27 (IBD)
Female IBD with high resilience
showed changes in brain-behavioural pattern
Scardillo et al.
2016 USA
Resilience as traits
45 adults (30 IBD)
Resilience was significantly higher
amongst individuals who adapted
well to their ostomy
Sehgal et al.a
2017 USA
Psychological resilience
113
Lower level of resilience was associated with anxiety and depression;
higher resilience predicted higher
QOL
Carlsen et al.
2017 USA
Trait resilience—predictor of
87 (30% adolescents, 62 CD) Self-efficacy and resilience were
adjustment
significant predictors of transition
readiness among adolescent and
young adults with IBD
Melinder et al.
2017 Sweden Psychosocial stress resilience
1799 (UC)
Low-to-moderate stress resilience
in adolescence correlated with
increased risk of CD and UC
Sirois and Hirsch
2017 Canada Trait resilience
152 adults (51.7% CD)
No significant difference between
resilient and thriving IBD patients
on perceived social support,
depressive symptoms, coping
efficacy, and illness acceptance
Skrautvol and Naden 2017 Norway Stress resilience
13 adults (7 CD)
Several themes were delineated,
notably “creating resilience
through integrative care”
Taylor et al.
2018 USA
Trait resilience
328 adults (145 UC)
Resilience positively and significantly associated with HRQOL
Acciari et al.
2019 Brazil
11 personal traits
104 adults (CD)
Individuals who were employed
without children and males were
more resilient than their counterparts; CD onset > 30 years old and
individuals who had complimentary activities were more resilient
Hwang and Yu
2019 Korea
A set of quality influenced by soci- 90 adults (76 CD)
Negative relation between resilience
ety, relationships and psychology
and depression; resilience was not
affected by clinical characteristics
in UC patients; lower income,
sleep disturbances, being unmarried negatively impacted resilience
in CD patients
Luo et al.
2019 China
Dynamic process of resilience
15 adults (10 CD)
Necessary cognitive traits and resilience-specific coping mechanisms
to deal constructively with IBD
CAM complementary and alternative medicine, CD Crohn’s disease, IBS irritable bowel disease, HCs healthy controls, HRQOL health-related
quality of life, UC ulcerative colitis, IBD inflammatory bowel disease
a

Abstracts/conference proceedings

reasonable to assume that they mutually influence each other,
as shown for psychiatric illnesses [100] and patients living
with HIV [101]. Disappointingly, only one study involving
40 community-based adult patients with self-reported IBD
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has investigated this issue in the IBD population so far. In
that study, the authors showed that individuals who seemed
more resilient were also more positive, used humour as a
coping mechanism, and placed their IBD in a wider life

Internal and Emergency Medicine (2020) 15:211–223
Fig. 2  Summary of the most
relevant features of stigmatisation and resilience and their
influencing factors. Low resilience may favour stigmatisation,
whilst resistance to stigma may
strengthen resilience. Inflammatory bowel disease is burdened
by a number of disease-specific
issues that favour social
stigmatisation and may affect
resilience
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Enacted
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Stigma
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Influencing factors
Individual-related
Disease-related
Social context
Support network

IBD-specific factors
Disturbed body image
Frequent toilet use
Immunosuppressants
Impaired sexual life
Ostomy/stoma bag

↑ Resilience

↑ Stigmatisation
Low
resilience
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to stigma

Influencing factors
Positive/negative attitudes
Coping mechanisms
Life perspectives

perspective [102]. Also, stigma was more evident in patients
with weak resilience, especially in those suffering from mental health disorders and in those lacking support networks.

comprehensive approaches addressing psychosocial aspects,
including stigma and resilience, will lead to a better quality
of life for patients with IBD.

Future directions
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Many unmet needs still exist in the IBD research agenda,
including a better understanding of its physiopathology,
reduction of diagnostic delays, discovery of more effective
and safer drugs, optimisation of existing therapies, improving patients’ adherence to the treatment plan, improving
patient’s quality of life, management of extraintestinal manifestations, and prevention of complications [103–110]. A
multidimensional approach is necessary for delivering highquality healthcare for IBD patients, but we are still far from
optimal management in real life [111]. Psychosocial aspects
of IBD still receive less attention than the more physical
aspects of the illness. According to current evidence, stigmatisation and resilience in IBD patients are not adequately
addressed in day-by-day clinical practice, even if they have
a great impact in terms of quality of life and coping with the
stress of a chronic illness. More holistic approaches to IBD
care are required that incorporate physical, psychological,
and social aspects of living with IBD.
Further research is required to better understand how
stigma and resilience influence patient engagement with
medical services, adherence to treatment, attitude towards
healthy living, and longer-term disease outcomes. Future
work to establish if and how stigmatisation can be reduced
and resilience improved is urgently needed. In the authors’
opinion, the combination of better medical treatments and
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